Clinical Trials Browser

Withdrawn × sacituzumab govitecan × Thoracic × Clear all

NCT07328490 2026-04-28

Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer

Phase 1/2 Withdrawn

Carcinoma, Small Cell, Small Cell Lung Carcinoma